An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to explore and evaluate whether a 2-dose schedule of Gardasil 9
among young and mid-adult women 16-45 years of age is generally safe and immunogenic, with an
antibody response that is not inferior to that observed of a 3-dose schedule of Gardasil 9
among women aged 16-26 years old. The investigators thought that having a 2-dose vaccination
regimen for individuals 16 to 45 would provide a more robust dataset than those of 27 to 45
years old.